Advanced search
Publication Cover
Acta Oncologica Volume 46, 2007 - Issue 5
Journal homepage
3,663
Views
61
CrossRef citations to date
0
Altmetric
ACTA ONCOLOGIA LECTURE

Forty years experience of treating cancer of unknown primary

Nicholas Pavlidis Department of Medical Oncology, School of Medicine, University of Ioannina, Ioannina, GreeceCorrespondence[email protected]
Pages 592-601 | Received 08 Dec 2006, Published online: 08 Jul 2009
 
Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days

Abstract

Cancer of unknown primary site (CUP) is not a rare tumour. It accounts as the seventh to eighth most frequently diagnosed cancer in a general medical oncology service. Since CUP is not a homogeneous disease and it consists of different favourable and unfavourable sub-sets, treatment of each clinicopathological entity requires a unique approach. The spectrum of therapeutic management includes both locoregional and systemic therapy and should intend to offer optimal benefit to favourable CUP patients and palliative care to unfavourable cases. This review article provides both a historical outline of CUP treatment as well as a helpful therapeutic guide to every oncologist who treats CUP patients.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related Research Data

A phase I/II study of leucovorin, carboplatin and 5-fluorouracil (LCF) in patients with carcinoma of unknown primary site or advanced oesophagogastric/pancreatic adenocarcinomas.
Source: Springer Science and Business Media LLC
Familial cancer of unknown primary.
Source: Springer Science and Business Media LLC
Computed tomography in the evaluation of metastatic adenocarcinoma from an unknown primary site. A retrospective study.
Source: Radiological Society of North America (RSNA)
Multicentric phase II study of cisplatin and etoposide in patients with metastatic carcinoma of unknown primary.
Source: Ovid Technologies (Wolters Kluwer Health)
Cancer patients without a known primary: Incidence and survival trends in Sweden 1960-2007
Source: Informa UK Limited
Computed tomography in search of cancer of unknown origin.
Source: American Medical Association (AMA)
Cisplatin in combination with either gemcitabine or irinotecan in carcinomas of unknown primary site: results of a randomized phase II study--trial for the French Study Group on Carcinomas of Unknown Primary (GEFCAPI 01).
Source: American Society of Clinical Oncology (ASCO)
Identification of clinical prognostic factors in patients with unknown primary tumors treated with a platinum-based combination.
Source: S. Karger AG
Mitomycin C, epirubicin and cisplatin versus mitomycin C alone as therapy for carcinoma of unknown primary origin
Source: S. Karger AG
Phase II study of epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) for carcinoma of unknown primary site.
Source: Elsevier BV
Cancers of unknown primary origin: current perspectives and future therapeutic strategies
Source: BMC
Angiogenesis in cancer of unknown primary: clinicopathological study of CD34, VEGF and TSP-1
Source: BMC
Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms
Source: Wiley
Epidemiologie, Prognosegruppen und therapeutische Strategie
Source: Springer Science and Business Media LLC
Unknown primary carcinoma, diagnosed as inflammatory breast cancer,and successfully treated with trastuzumab and vinorelbine.
Source: Springer Science and Business Media LLC
A new entity of abdominal squamous cell carcinoma of unknown primary
Source: Wiley
A phase II study of mitomycin C, cisplatin and continuous infusion 5-fluorouracil (MCF) in the treatment of patients with carcinoma of unknown primary site.
Source: Springer Science and Business Media LLC
Development and Validation of a Prognostic Model to Predict the Length of Survival in Patients With Carcinomas of an Unknown Primary Site
Source: American Society of Clinical Oncology (ASCO)
Microvessel density in unknown primary tumors.
Source: Wiley
A phase II study of paclitaxel plus cisplatin chemotherapy in an unfavourable group of patients with cancer of unknown primary site.
Source: Oxford University Press (OUP)
5-fluorouracil, adriamycin, and mitomycin in the treatment of adenocarcinoma of unknown primary.
Source: American Society of Clinical Oncology (ASCO)
Treatment of the patient with adenocarcinoma of unknown origin.
Source: Wiley
Evaluation of six tumor markers in patients with carcinoma of unknown primary
Source: Wiley
Peritoneal papillary serous carcinoma with long-term survival.
Source: Wiley
Cisplatin and 5-Fluorouracil for Metastatic Squamous Cell Carcinoma from Unknown Primary
Source: Informa UK Limited
Cervical lymph node metastases from unknown primary tumours. Results from a national survey by the Danish Society for Head and Neck Oncology.
Source: Elsevier BV
Carboplatin plus paclitaxel in unknown primary carcinoma : A phase II hellenic cooperative oncology group study
Source: American Society of Clinical Oncology (ASCO)
VAC (vincristine, adriamycin, cyclophosphamide) chemotherapy for metastatic carcinoma from an unknown primary site
Source: Elsevier BV
A randomized Phase II trial in patients with carcinoma of an unknown primary site.
Source: Wiley
Treatment and prognosis of metastatic carcinoma of unknown primary: analysis of 100 patients.
Source: Wiley
Phase II trial of cisplatin for adenocarcinoma of unknown primary site
Source: Elsevier BV
Phase II trial of paclitaxel, carboplatin, and etoposide in advanced poorly differentiated neuroendocrine carcinoma : A minnie pearl cancer research network study
Source: American Society of Clinical Oncology (ASCO)
Alternative bimonthly cycles of doxorubicin, cyclophosphamide, and etoposide, cisplatin with hematopoietic growth factor support in patients with carcinoma of unknown primary site.
Source: Wiley
Fluorouracil, doxorubicin, cisplatin and altretamine in the treatment of metastatic carcinoma of unknown primary.
Source: Elsevier BV
A multicentre phase II study of carboplatin and prolonged oral etoposide in the treatment of cancer of unknown primary site (CUPS).
Source: Springer Science and Business Media LLC
A phase II trial of biochemical modulation using N-phosphonacetyl-L-aspartate, high-dose methotrexate, high-dose 5-fluorouracil, and leucovorin in patients with adenocarcinoma of unknown primary site.
Source: Wiley
Treatment of patients with isolated axillary nodal metastases from an occult primary carcinoma consistent with breast origin.
Source: Wiley
A Randomized Study of Two Combination-Chemotherapy Regimens
Source: Massachusetts Medical Society
Unknown Primary Carcinoma: Randomised Studies are Needed to Identify Optimal Treatments and Their Benefits
Source: Elsevier BV
Carcinoma of unknown primary site: Phase II trials with docetaxel plus cisplatin or carboplatin
Source: Elsevier BV
Hepatic metastases from an unknown primary neoplasm (UPN): survival, prognostic indicators and value of extensive investigations
Source: Elsevier BV
Predictive value of seven preoperative prognostic scoring systems for spinal metastases
Source: Springer Science and Business Media LLC
Original article: Subsets of tumors responsive to cisplatin or carboplatin combinations in patients with carcinoma of unknown primary site A Hellenic Cooperative Oncology Group Study
Source: Elsevier BV
Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site
Source: Wiley
Long term follow-up after treatment with paclitaxel, carboplatin, and etoposide
Source: Wiley
The role of etoposide in the treatment of poorly differentiated carcinoma of unknown primary site
Source: Wiley
Papillary serous carcinoma of the peritoneum. A review of 33 cases treated with platin-based chemotherapy.
Source: Wiley
Overexpression and prevalence of molecular markers in patients with cancer of unknown primary (CUP)
Source: American Society of Clinical Oncology (ASCO)
Prognostic Variables and Treatment Results
Source: Ovid Technologies (Wolters Kluwer Health)
Phase II study of oral administration of etoposide for patients with well- and moderately-differentiated adenocarcinomas of unknown primary site
Source: Elsevier BV
Molecular and cytogenetic studies in the diagnosis of patients with poorly differentiated carcinomas of unknown primary site.
Source: American Society of Clinical Oncology (ASCO)

Linking provided by 
Download PDF

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.